adalimumab

Overview

Adalimumab is a therapeutic monoclonal antibody used as an anti-inflammatory biologic agent. It is a tumor necrosis factor-alpha (TNF-α) inhibitor, meaning it binds TNF-α and blocks its proinflammatory activity. By suppressing TNF-driven immune signaling, adalimumab is used in chronic immune-mediated inflammatory diseases, including psoriasis, psoriatic arthritis, inflammatory bowel disease, uveitis, and other autoimmune or autoinflammatory conditions.

In biomedical research, adalimumab is frequently used as a reference anti-TNF therapy, a comparator in comparative effectiveness studies, and a benchmark for biosimilar development and analytical characterization. Recent studies have also examined its pharmacokinetics, therapeutic drug monitoring, safety in real-world cohorts, and mechanistic effects on immune cells such as monocyte-derived macrophages and T helper cell responses.

Focus of Latest Publications

Recent publications have examined adalimumab across diverse inflammatory conditions and treatment contexts, with substantial focus on the emergence and real-world adoption of adalimumab biosimilars. Following market introduction in 2023, studies documented switching and switch-back patterns in patients transitioning to biosimilar formulations in the United States, while population-based research from British Columbia evaluated longer-term utilization patterns after mandatory biosimilar-switching policies. Additional work assessed the clinical impact of multiple switches between adalimumab biosimilar ABP 501 and the reference product in psoriasis.

Comparative efficacy and safety studies positioned adalimumab against both emerging therapies and other biologic agents. Seven-year data from the SELECT-COMPARE trial compared long-term safety and efficacy of upadacitinib with adalimumab in rheumatoid arthritis. Analyses of serious infection risk in psoriatic arthritis and psoriasis populations revealed similar incidence rates between adalimumab and secukinumab at 1 and 3 years, though infliximab demonstrated higher infection risk. Comparative assessments also addressed cardiac safety concerns in inflammatory bowel disease, while a case report documented an association between adalimumab use and development of IgA nephropathy in a rheumatoid arthritis patient, underscoring the importance of renal monitoring during therapy.

Efficacy of adalimumab and its biosimilars was demonstrated across multiple conditions. A 52-week prospective study confirmed safety and effectiveness in pyoderma gangrenosum, while long-term pediatric uveitis data demonstrated sustained benefits with weekly dose escalation in refractory cases. In psoriasis, therapeutic drug monitoring strategies employing trough-level guided dose adjustment achieved a 37.5% improvement in PASI90 response compared to standard care. Mechanistic investigations revealed that adalimumab reprograms M1 macrophages to attenuate Th1/Th17 responses in Behçet's uveitis and Vogt-Koyanagi-Harada syndrome. Safety and effectiveness of adalimumab biosimilar formulations were specifically evaluated in hidradenitis suppurativa.

In pediatric populations, adalimumab remains one of only three biologic therapies approved for inflammatory bowel disease treatment, alongside infliximab and ustekinumab. A narrative review examining the benefit-risk balance of advanced therapies in pediatric IBD highlighted critical gaps between adult and pediatric evidence and advocated for a shift from empirical extrapolation of adult data to precision medicine approaches integrating real-world evidence, predictive modeling, and shared decision-making to optimize therapeutic strategies.